Aisling Capital overview
Stories about Aisling Capital
Aisling Capital raises $280 mln for fund
Aisling Capital, a late-stage life sciences investment firm, has closed its latest fund at $280 million. The fund will focus on "helping clinical stage ventures improve global health."
KKR and Aisling Capital launches Ajax Health
KKR and Aisling Capital have formed a new platform Ajax Health, which will source and provide operational and financial supporting emerging medical device companies. No financial terms were disclosed. Duke Rohlen will lead Ajax.
F2G raises $60 mln
F2G Ltd said June 20 that it raised $60 million in financing led by Sectoral Asset Management. Novo A/S, Aisling Capital and Brace Pharma Capital also invested. Existing investors Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital each participated in the round. F2G is a UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infection.
Fund performance: Asia Alternatives, Aisling, Insight lead late-decade venture portfolio
Several funds already are posting good, early returns in a Calpers portfolio that is heavy with multi-stage, late-decade funds
KKR leads $45 mln round for Spirox
Spirox Inc. said Tuesday it closed a $45 million Series C round led by KKR. Also participating in the round were HealthQuest Capital along with existing investors Aisling Capital, Aperture Venture Partners and Venrock. Menlo Park, California-based Spirox is a medical device company.
Aisling Capital contact information
Offices
489 5th Avenue 10th Floor, New York, 10017, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Robert Wenzel | Job titleChief Financial Officer and Chief Compliance Officer | LocationNew York, United States | Email  ------ |
| Mr. Steven A Elms | Job titleManaging Partner | LocationNew York, United States | Email ------ |
| Dr. Andrew Schiff | Job titleManaging Partner | LocationNew York, United States | Email -------- |
| Dr. Eric Aguiar | Job titlePartner | LocationNew York, United States | Email --------- |
Aisling Capital funds managed
Closed funds: 5
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size --------- | Close dateMay 2021 | Strategy ----- | |
Fund size ------ | Close dateJun 2017 | Strategy ---------- | |
Fund size ----- | Close dateNov 2008 | Strategy ----- | |
Stories that mention Aisling Capital
VC-backed Monte Rosa Therapeutics debuts IPO
Monte Rosa Therapeutics Inc, a developer of small molecule precision medicines, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share.
Elevation Oncology nets $32.5m Series A
New York City-based Elevation Oncology, a clinical-stage biopharmaceutical company, has raised $32.5 million in Series A financing.
Medical device firm Ajax Health rakes in more than $85 mln
Ajax Health, a medical device firm, has raised more than $85 million in funding. HealthQuest Capital led the round with participation from Aisling Capital and Polaris Partners.
BridgeBio Pharma racks up $299.2 mln
BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, has raised $299.2 million in funding. KKR and Viking Global Investors led the round with participation from other investors that included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, Hercules Capital and Sequoia Capital.
Biotech firm Atreca rakes in $125 mln Series C
Redwood City, California-based Atreca Inc, a biotechnology company, has secured $125 million in Series C financing. The investors included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.